| 摘要 |
PCT No. PCT/EP90/01663 Sec. 371 Date Apr. 14, 1992 Sec. 102(e) Date Apr. 14, 1992 PCT Filed Sep. 4, 1990 PCT Pub. No. WO91/04974 PCT Pub. Date Apr. 18, 1991.The invention concerns compounds of formula I <IMAGE> (I) where R1 is hydrogen, C1-C6-alkyl, C2-C6-alkenyl or C3-C7-cycloalkyl, R2 is C1-C6-alkyl, C2-C6-alkenyl, cyano, carboxy [carbonyl substituted by hydroxyl], C1-C6-alkyl, C1-C6-alkoxy, amino, C1-C6-alkylamino, di-C1-C6-alkylamino or hydrazino or R1 and R2 together are C2-C6-alkylidene or C3-C6-cycloalkylidene or R1 and R2, together with the carbon atoms to which they are attached, form a C3-C7-spirocycle, n is 0 or 1, R3 is hydrogen, C1-C8-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C7-cycloalkyl, benzyl, carboxy-C1-C6-alkyl, C1-C6-alkyloxycarbonyl-C1-C6-alkyl or di-C1-C6-alkyloxophosphinyl-C1-C6-alkyl and R4-R 6 are as in the specification. These compounds of formula I serve for the preparation of medicaments to inhibit erythrocyte and thrombocyte aggregation. Therefore, these compounds are useful for the treatment of diseases where these aggregations occur such as arterial occlusive or ischaemic conditions, venous insufficiency or diabetes mellitus. |
